Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Return on Equity (2017 - 2026)

Lexaria Bioscience's Return on Equity history spans 10 years, with the latest figure at 1.76% for Q1 2026.

  • Quarterly results put Return on Equity at 1.76% for Q1 2026, down 60.0% from a year ago — trailing twelve months through Feb 2026 was 1.76% (down 60.0% YoY), and the annual figure for FY2025 was 2.31%, down 120.0%.
  • Return on Equity for Q1 2026 was 1.76% at Lexaria Bioscience, up from 3.02% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.3% in Q1 2022 to a low of 3.06% in Q3 2025.
  • The 5-year median for Return on Equity is 1.16% (2025), against an average of 1.34%.
  • The sharpest move saw Return on Equity soared 112bps in 2024, then crashed -240bps in 2025.
  • Year by year, Return on Equity stood at 0.93% in 2022, then tumbled by -112bps to 1.97% in 2023, then surged by 57bps to 0.86% in 2024, then crashed by -253bps to 3.02% in 2025, then surged by 42bps to 1.76% in 2026.
  • According to Business Quant data, Return on Equity over the past three periods came in at 1.76%, 3.02%, and 3.06% for Q1 2026, Q4 2025, and Q3 2025 respectively.